A fully 3D-printed versatile tumor-on-a-chip allows multi-drug screening and correlation with clinical outcomes for personalized medicine

Optimal clinical outcomes in cancer treatments could be achieved through the development of reliable, precise ex vivo tumor models that function as drug screening platforms for patient-targeted therapies. Microfluidic tumor-on-chip technology is emerging as a preferred tool since it enables the comp...

Full description

Saved in:
Bibliographic Details
Published in:Communications biology 2023-11, Vol.6 (1), p.1157-1157, Article 1157
Main Authors: Steinberg, Eliana, Friedman, Roy, Goldstein, Yoel, Friedman, Nethanel, Beharier, Ofer, Demma, Jonathan Abraham, Zamir, Gideon, Hubert, Ayala, Benny, Ofra
Format: Article
Language:English
Subjects:
13
13/106
13/107
13/62
631/1647/277
631/67/70
Biocompatibility
Biology
Biomedical and Life Sciences
Cancer therapies
Clinical outcomes
Drug screening
Life Sciences
Microenvironments
Microfluidics
Precision medicine
Spheroids
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Optimal clinical outcomes in cancer treatments could be achieved through the development of reliable, precise ex vivo tumor models that function as drug screening platforms for patient-targeted therapies. Microfluidic tumor-on-chip technology is emerging as a preferred tool since it enables the complex set-ups and recapitulation of the physiologically relevant physical microenvironment of tumors. In order to overcome the common hindrances encountered while using this technology, a fully 3D-printed device was developed that sustains patient-derived multicellular spheroids long enough to conduct multiple drug screening tests. This tool is both cost effective and possesses four necessary characteristics of effective microfluidic devices: transparency, biocompatibility, versatility, and sample accessibility. Compelling correlations which demonstrate a clinical proof of concept were found after testing and comparing different chemotherapies on tumor spheroids, derived from ten patients, to their clinical outcomes. This platform offers a potential solution for personalized medicine by functioning as a predictive drug-performance tool. A unique 3D-printed device made of sustainable materials was developed to produce 3D spheroids from primary cells and perform drug screening assays in a biomimetic environment.
ISSN:2399-3642
2399-3642
DOI:10.1038/s42003-023-05531-5